Abstract
Currently, there is no existing data on the role of asprosin and meteorin-like protein (Metrnl) in the pathogenesis of obesity in children.
Purpose of the study. To assess the relationship between the levels of adipomio-cins asprosin and Metrnl with body composition, metabolic parameters, and hormonal profile in obese adolescents.
Material and methods. The study included 35 participants aged 14 to 17 years. The main study group consisted of 20 overweight and obese adolescents. The control group consisted of 15 conditionally healthy adolescents with normal body weight. All study participants underwent anthropometric measurements, assessment of body composition using bioimpedansmetry (Inbody 770), three-time measurement of blood pressure, and laboratory examinations (glucose, lipid profile, insulin, asprosin, Metrnl, cholecystokinin, leptin, resistin, irisin, and glucagon-like peptide-1 and 2 (GLP-1 and GLP-2).
Results. Metrnl levels were significantly correlated with most anthropometric and metabolic parameters, including the surrogate indices of insulin resistance HOMA-IR, SPISE, and TyG, as well as with leptin and GLP-1 (Figures 1 and 2). Asprosin did not show significant correlations with any of the studied parameters (all p>0.05).
Conclusion. Metrnl, unlike asprosin, proved to be a highly sensitive marker of metabolic disorders associated with obesity in adolescence. Elevated Metrnl levels in obesity may be a manifestation of an adaptive but ultimately ineffective compensatory response to insulin resistance, or it may reflect a state of «metrnl resistance.» The combined determination of these peptide levels over time can help in risk stratification and determining the stage of metabolic disorders in children.
Authors and affiliations
M.V. Kovarenko(1), Yu.G. Samoilova(1, 2), D.V. Podchinenova(1, 2),, O.A. Oleynik(1, 2), M.V. Matveeva(1, 2), D.A. Kudlay(3–5)
1-Federal State Autonomous Educational Institution of Higher Education “Novosibirsk National Research State University”,
Pirogova str., 1, Novosibirsk, 630090, Russian Federation; 2-Siberian State Medical University of the Ministry of Health
of the Russian Federation, Moskovsky trakt, 2, Tomsk, 634050, Russian Federation; 3-Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
(Sechenov University), Trubetskaya str., 8, build. 2, Moscow, 119991, Russian Federation; 4-Federal State Budget Educational
Institution of Higher Education M.V. Lomonosov Moscow State University, Leninskie Gory, 1, Moscow, 119991, Russian Federation;
5-The Federal Scientific “State Research Center Institute of Immunology” of the Federal Medical and Biological Agency of Russia, Kashirskoye Shosse, 24, 115522, Moscow, Russian Federation
References
Franks P.W., Hanson R.L., Knowler W.C., Sievers M.L., Bennett P.H., Looker H.C. Childhood obesity, other cardiovascular risk factors, and premature death. N. Engl. J. Med. 2010; 362: 485–93. DOI: 10.1056/NEJMoa0904130
2. Hampl S.E., Hassink S.G., Skinner A.C., Armstrong S.C., Barlow S.E., Bolling C.F., Avila Edwards K.C. et al. Clinical practice guideline guidance for the clinician in rendering pediatric care clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023; 151 (2): e2022060641. DOI: 10.1542/peds.2022-060640/1434810/peds_2022060640.pdf
3. Frigolet M.E., Gutiérrez-Aguilar R. The colors of adipose tissue. Gac Med Mex. 2020; 156 (2): 142–9. DOI: 10.24875/GMM.M20000356.
4. Nakamura K., Fuster J.J., Walsh K. Adipokines: a link between obesity and cardiovascular disease. J. Cardiol. 2014; 63 (4): 250–9. DOI: 10.1016/j.jjcc.2013.11.006.
5. Romere C., Duerrschmid C., Bournat J., Constable P., Jain M., Xia F., Saha P.K., Del Solar M., Zhu B., York B., Sarkar P., Rendon D.A., Gaber M.W., LeMaire S.A., Coselli J.S., Milewicz D.M., Sutton V.R., Butte N.F., Moore D.D., Chopra A.R. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016; 165 (3): 566–79. DOI: 10.1016/j.cell.2016.02.063.
6. Wang M., Yin C., Wang L., Liu Y., Li H., Li M. et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2019; 75: 205–12. DOI: 10.1159/000503808].
7. Moradi N., Fadaei R., Roozbehkia M., Nourbakhsh M., Razzaghy-Azar M., Larijani B. Meteorin-like Protein and Asprosin Levels in Children and Adolescents with Obesity and Their Relationship with Insulin Resistance and Metabolic Syndrome. Lab Med. 2023; 54 (5): 457–63. DOI: 10.1093/labmed/lmac152.
8. Sünnetçi Silistre E., Hatipoğl H.U. Increased serum circulating asprosin levels in children with obesity. Pediatr Int. 2020; 62 (4): 467–76. DOI: 10.1111/ped.14176.
9. Kim S.H., Kim S.E., Chun Y.H. The association of plasma asprosin with anthropometric and metabolic parameters in Korean children and adolescents. Front Endocrinol (Lausanne). 2024; 15: 1452277. DOI: 10.3389/fendo.2024.1452277.
10. Long W., Xie X., Du C., Zhao Y., Zhang C., Zhan D., Li Z. et al. Decreased Circulating Levels of Asprosin in Obese Children. Horm. Res. Paediatr. 2019; 91: 271–7. DOI: 10.1159/000500523,
11. Corica D., Aversa T., Currò M., Tropeano A., Pepe G., Alibrandi A., Lentile R. Et al. Asprosin serum levels and glucose homeostasis in children with obesity. Cytokine. 2021; 142: 155477. DOI: 10.1016/j.cyto.2021.155477.
12. Dulkadir R., Turna Saltoglu G., Gunes A.. Asprosin and Neuregulin 4 in Obesity in Children. Medicina (Kaunas). 2025; 61 (4): 723. DOI: 10.3390/medicina61040723.
13. Rao R.R., Long J.Z., White J.P., Svensson K.J., Lou J., Lokurkar I., Jedrychowski M.P. et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014; 157: 1279–91. DOI: 10.1016/j.cell.2014.03.065.
14. Löffler D., Landgraf K., Rockstroh D., Schwartze J.T., Dunzendorfer H., Kiess W., Körner A. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int. J. Obes. 2017; 41: 112–9. DOI:10.1038/ijo.2016.180.
15. Li Z.-Y., Song J., Zheng S.-L., Fan M.B., Guan Y.F., Qu Y., Xu J., Wang P., Miao C.Y. Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. Diabetes. 2015; 64 (12): 4011–22. DOI: 10.2337/db15-0274.
16. Gholamrezayi A., Mohamadinarab M., Rahbarinejad P., Fallah S., Barez S.R., Setayesh L., Moradi N. et al. Characterization of the serum levels of meteorin-like in patients with inflammatory bowel disease and its association with inflammatory cytokines. Lipids Health Dis. 2020; 19 (1): 230. DOI: 10.1186/s12944-020-01404-6.
17. Onalan E., Cavli C., Dogan Y., Onalan E., Gozel N., Buran I., Yakar B. et al. Low serum levels of meteorin-like/subfatin: An indicator of diabetes mellitus and insulin resistance? Endokrynol Pol. 2020; 71 (5): 397–403. DOI: 10.5603/EP.a2020.0038.
18. Fouani F.Z., Fadaei R., Moradi N., Zandieh Z., Ansaripour S., Yekaninejad M.S., Vatannejad A. et al. Circulating levels of meteorin-like protein in polycystic ovary syndrome: A case-control study. PloS One. 2020; 15 (4): e0231943. DOI: 10.1371/journal.pone.0231943.
19. Lappas M. Maternal obesity and gestational diabetes decrease metrnl concentrations in cord plasma. J. Matern Fetal Neonatal Med. 2021; 34 (18): 2991–5. DOI: 10.1080/14767058.2019.1676713.
20. Ferns G.A., Fekri K., Shahini Shams Abadi M., Banitalebi Dehkordi M., Arjmand M.H. A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease. Arch Physiol Biochem. 2021; 1–7. DOI: 10.1080/13813455.2021.1899239.
21. AlKhairi I., Cherian P., Abu-Farha M., Madhoun A.A., Nizam R., Melhem M., Jamal M. et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019; 8: 1283. DOI: 10.3390/cells8101283.
22. Wang K., Li F., Wang C., Deng Y., Cao Z., Cui Y., Xu K et al. Serum levels of meteorin-like (Metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance. Med Sci Monit. 2019; 25: 2337–43. DOI: 10.12659/MSM.915331.
23. Nedeva I., Assyov Y., Karamfilova V., Kamenov Z., Dobrev P., Velikova T., Vodenicharov V. New Players in Metabolic Syndrome. Metabolites. 2025; 15 (6): 380. DOI: 10.3390/metabo15060380.
24. Sobieh B.H., Kassem D.H., Zakaria Z.M., El-Mesallamy H.O.. Potential emerging roles of the novel adipokines adipolin/CTRP12 and meteorin-like/METRNL in obesity-osteoarthritis interplay. Cytokine. 2021; 138: 155368. DOI: 10.1016/j.cyto.2020.155368.
25. Alizadeh H., Alizadeh A. Association of meteorin-like hormone with insulin resistance and body composition in healthy Iranian adults. Diabetes Metab Syndr. 2020; 14 (5): 881–5. DOI: 10.1016/j.dsx.2020.05.031].
26. Ugur K., Erman F., Turkoglu S., Aydin Y., Aksoy A., Lale A., Karagöz Z.K. et al. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome. Eur Rev Med Pharmacol Sci. 2022; 26 (6): 2124–33. DOI:10.26355/eurrev_202203_28360.
27. Du Y., Ye X., Lu A., Zhao D., Liu J., Cheng J., Yang T. Inverse relationship between serum metrnl levels and visceral fat obesity (VFO) in patients with type 2 diabetes. Diabetes Res Clin Pract. 2020; 161: 108068. DOI: 10.1016/j.diabres.2020.108068.
28. Hao L., Liu L., Lin H., Guo S., Lian B., Yin C., Xiao Y. et al. Elevated serum METRNL levels in children with obesity and its association with insulin resistance. Eur. J. Pediatr. 2025; 184 (9): 543. DOI: 10.1007/s00431-025-06362-8.
29. Васюкова О.В., Окороков П.Л., Малиевский О.А., Неймарк А.Е., Зорин Е.А., Яшков Ю.И., Бурмицкая Ю.В. и др. Клинические рекомендации «Ожирение у детей». Ожирение и метаболизм. 2024; 21 (4): 439–53. [Vasyukova O.V., Okorokov P.L., Malievskij O.A., Nejmark A.E., Zorin E.A., YAshkov YU.I., Burmickaya YU.V. et al. Clinical guidelines «Obesity in children». Obesity and metabolism. 2024; 21 (4): 439–53. DOI:10.14341/omet13194 (in Russian)].
30. Васюкова О.В. Ожирение у детей и подростков: критерии диагноза. Ожирение и метаболизм. 2019; 16 (1): 70–3. [Vasyukova O.V. Obesity in children and adolescents: diagnosis criteria. Obesity and metabolism. 2019; 16 (1): 70–3. DOI: org/10.14341/omet10170 (in Russian)].
31. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet. 2014; 384 (9943): 618–25. DOI: 10.1016/S0140-6736(14)61217-4. PMID: 25131981.
32. Arellano-Ruiz P., Garcia-Hermoso A., Cavero-Redondo I., Pozuelo-Carrascosa D., Martinez-Vizcaino V., Solera-Martinez M. Homeostasis Model Assessment Cut-off Points Related to Metabolic Syndrome in Children and Adolescents: A Systematic Review and Meta-Analysis. Eur. J. Pediatr. 2019; 178: 1813–22. DOI: 10.1007/s00431-019-03464-y.
33. Keskin M., Kurtoglu S., Kendirci M. et al. Homeostasis model assessment is more reliable than the fasting glucose/ insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005; 115 (4): e500–3. DOI: 10.1542/peds.2004-1921/
34. Tantari G., Bassi M., Pistorio A., Minuto N., Napoli F., Piccolo G., La Valle A. et al. SPISE INDEX (Single point insulin sensitivity estimator): indicator of insulin resistance in children and adolescents with overweight and obesity. Front Endocrinol (Lausanne). 2024; 15: 1439901. DOI: 10.3389/fendo.2024.1439901.
35. D’Souza K., Mercer A., Mawhinney H., Pulinilkunnil T., Udenigwe C.C., Kienesberger P.C. Whey peptides stimulate differentiation and lipid metabolism in adipocytes and ameliorate lipotoxicity-induced insulin resistance in muscle cells. Nutrients. 2020; 12: 425. DOI: 10.3390/nu12020425.
36. Calcaterra V., Montalbano C., de Silvestri A., Pelizzo G., Regalbuto C., Paganelli V., Albertini R. Triglyceride Glucose Index as a Surrogate Measure of Insulin Sensitivity in a Caucasian Pediatric Population. J. Clin. Res. Pediatr. Endocrinol. 2019. DOI: 10.4274/jcrpe. galenos.2019.2019.0024.
37. Angelini G., Russo S., Mingrone G. Incretin hormones, obesity and gut microbiota. Peptides. 2024; 178: 171216. DOI: 10.1016/j.peptides.2024.171216.